RELYVRIO (sodium phenylbutyrate and taurursodiol)

Self-Administration – oral

Indications for Prior Authorization:
  • Amyotrophic Lateral Sclerosis (ALS) - Indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.

Coverage Criteria:

For diagnosis of amyotrophic lateral sclerosis (ALS):

  • Dose does not exceed 6 g sodium phenylbutyrate/2 g taurursodiol (2 packets) daily; AND

  • Patient is 18 years of age or older; AND

  • Diagnosis of ALS is supported by neurogenic changes in electromyography (EMG); AND

  • Patient has had ALS symptoms for less than or equal to 18 months; AND

  • Patient has a percent (%) forced vital capacity (%FVC) or slowed vital capacity (%SVC) greater than or equal to 60% at the start of treatment; AND

  • Patient does not require permanent noninvasive ventilation or invasive ventilation; AND

  • Patient has had an inadequate response or intolerable side effects to riluzole, or patient will continue to take riluzole; AND

  • Prescribed by or in consultation with a neurologist with expertise in the diagnosis of ALS

Reauthorization Criteria:

For diagnosis of amyotrophic lateral sclerosis (ALS):

  • Dose does not exceed 6 g sodium phenylbutyrate/2 g taurursodiol (2 packets) daily; AND

  • Documentation of positive response to therapy (e.g., slowed disease progression from baseline)

Coverage Duration:
  • Initial: 6 months

  • Reauthorization: 1 year

Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:
  • Dosing

    • One packet should be emptied into a cup containing 8 ounces of room-temperature water and stirred vigorously. It should be taken orally or administered via a feeding tube within 1 hour of preparation and before a snack or meal.

    • The reconstituted suspension may be stored for up to 1 hour at room temperature. Any unused reconstituted suspension should be discarded after 1 hour.

  • Patients with enterohepatic circulation disorder, pancreatic disorders, or intestinal disorders may lead to a decreased absorption of either component of the drug, and consultation with a specialist should be considered.

  • Relyvrio has a high sodium content (1 packet contains about 464 mg sodium). Sodium intake should be monitored in patients with sodium sensitivity.

Policy Updates:
  • 06/01/2023 – New policy approved by P&T
References:
  • Paganoni S, Macklin EA, Hendrix S, et al. Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine. 2020;383(10):919-930. 

  • Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force. European Journal of Neurology. 

  • Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle & Nerve. 2021;63(1):31-39. 

  • ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/study/NCT03127514. Accessed May 26, 2022. 

  • Galvez-Jimenez N, Goyal NA. Disease-modifying treatment of amyotrophic lateral sclerosis. UpToDate Web site. http://www.uptodate.com. Accessed May 26, 2022. 

  • Elman LB, McCluskey, L. Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease. UpToDate Web site. http://www.uptodate.com. Accessed May 26, 2022. 

  • Relyvrio Prescribing Information. Amylyx Pharmaceuticals, Inc. Cambridge, MA. September 2022. 

Last review date: June 1, 2023

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone